Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07526948

Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV

This is a research study about the effects of vaginal estradiol compared to moisturizer on vaginal symptoms of menopause and the microbiome in women with HIV. This research study aims to understand how vaginal products affect the aging of the female genital tract in women living with HIV who are menopausal or perimenopausal and have vaginal or urinary symptoms. There is a comparison group of women who are living without HIV. Participants with HIV and vaginal or urinary menopausal symptoms (e.g., dryness, irritation, soreness, itching, pain with sex, dysuria, urgency, or frequent urinary tract infections) will be asked to apply vaginal estradiol or a vaginal moisturizer (Replens). Participants who have vaginal or urinary menopausal symptoms and do not have HIV will receive vaginal estradiol.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • female
  • at least 40 years old
  • menopausal (no menses in 12 months) within 2 years of last menstrual period or perimenopausal in the late menopausal transition, defined as an interval of amenorrhea greater than or equal to 60 days
  • have symptoms of the genitourinary syndrome of menopause (GSM) which developed within the prior 2 years. Symptoms of GSM include vaginal symptoms including dryness, soreness, itching, irritation and dyspareunia and/or urinary symptoms including urgency, frequency and recurrent urinary tract infections (UTIs)

Exclusion criteria

  • Unexplained or unevaluated abnormal genital bleeding
  • Current or suspected pregnancy
  • Desired pregnancy
  • If less than 55 years old, have had a hysterectomy and have at least one ovary (as menopause cannot be determined in this case by amenorrhea alone)
  • Pelvic or vaginal surgery in the prior 60 days
  • Used systemic reproductive hormones in the last 2 months
  • Used antibiotics in the last 30 days
  • Used immunosuppressive medications in the prior 60 days including biologics, chemotherapeutics or post transplant immunosuppressive medications
  • Used any vaginal or vulvar preparations in the last month
  • Current active vaginal infection diagnosed at study entry
  • Any serious disease or condition that may interfere with study compliance
  • Current or previous history of breast cancer or estrogen dependent cancer (e.g., ovarian, endometrial)
  • Current or previous history of deep vein thrombosis or pulmonary embolism
  • Current or previous history of myocardial infarction or stroke
  • Known clotting disorder including Protein C, Protein S and antithrombin deficiency, Factor V Leiden or prothrombin mutations
  • Known severe liver disease including cirrhosis or active Hepatitis B
  • Known allergic reaction to Vagifem (estradiol vaginal tablet) or Replens

Treatment and study plan

Vaginal estradiol tablets

Drug

Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 16 weeks.

Other names: Vagifem

Vaginal moisturizer

Other

Using a pre-loaded single-use plastic applicator, participants will insert one vaginal moisturizer applicator intravaginally twice weekly for the duration of the study for a total of 12 weeks.

Other names: Replens

Primary outcomes

  1. Change in the vaginal microbiome (bacteria) as defined by the change in alpha diversity

    Time frame: From Baseline to 16 weeks

    Changes in the vaginal microbiome as defined by the change in alpha diversity from baseline to 16 weeks will be assessed. It is hypothesized that this may be a biomarker for improvement in vaginal health. Lower alpha diversity would indicate a favorable change in the microbiome.

Secondary outcomes

  1. Change in genitourinary syndrome of menopause (GSM) symptoms as defined by the composite GSM symptom index

    Time frame: From Baseline to 16 weeks

    Using a survey administered at each visit, participants will rate the severity of five vaginal (dryness, itching, irritation, soreness, and dyspareunia) and three urinary (frequency, urgency, recurrent UTIs) symptoms based on a four-point scale (0=none, 1=mild, 2=moderate, 3=severe). A composite GSM symptom index will be calculated as the mean severity of the corresponding symptoms at each visit. A higher score indicates increased severity of symptoms.

    It is anticipated that both vaginal estradiol and the vaginal moisturizer will lead to improvement in the symptoms of the genitourinary syndrome of menopause.

Study contacts

Contact information is provided by the study sponsor or research team.

Kerry J Murphy, MD

CONTACT

[email protected]

718-839-7885

Marla J Keller, MD

CONTACT

[email protected]

718-430-3240

Sponsors and collaborators

Lead sponsor

Albert Einstein College of Medicine

Other

Collaborators

  • National Institute on Aging (NIA)
  • Yale University
  • Zymo Research

Registry information

Official study title

Vaginal Estradiol Versus Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms, Dysbiosis and Markers of Latency Reversal in Menopausal Women Living With HIV

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Apr 14, 2026
Registry last updated
Jul 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.